CatalystFDA/Bio

XtalPi Submits U.S. FDA IND Application for KQTD-126, a Potential First-in-Class, Gut-Restricted Pan-TRK Inhibitor for Chronic Intestinal Pain

FDA IND submission for first-in-class pan-TRK inhibitor targeting chronic intestinal pain.

What changed

FDA IND submission for first-in-class pan-TRK inhibitor targeting chronic intestinal pain.

Why it matters

FDA IND submission for first-in-class pan-TRK inhibitor targeting chronic intestinal pain. — impact context not separately stored; see What changed.

Sources